FDA Accepts Pharming's Resubmission for Joenja in Younger APDS Patients
Event summary
- FDA accepted Pharming's resubmitted sNDA for Joenja (leniolisib) to treat children aged 4 to 11 with APDS, targeting a PDUFA date of October 24, 2026.
- Resubmission includes additional data on analytical methods for production batch testing, following a Complete Response Letter in January 2026.
- Separate sNDA for lower-weight pediatric patients planned for the second half of 2026.
- Phase III study data showed improvements in lymphadenopathy and naïve B cells over 12 weeks, with mild to moderate adverse events reported.
The big picture
Pharming's resubmission for Joenja represents a critical step in addressing a significant unmet need in the treatment of APDS, a rare primary immunodeficiency. The acceptance of the sNDA by the FDA highlights the growing focus on pediatric rare disease treatments and the strategic importance of expanding the therapeutic reach of existing drugs. If approved, Joenja could become the first treatment option for younger APDS patients in the U.S., potentially positioning Pharming as a leader in this niche market.
What we're watching
- Regulatory Timeline
- Whether the FDA will approve Joenja for this younger age group by the PDUFA target date of October 24, 2026.
- Market Expansion
- The pace at which Pharming can expand Joenja's approval to lower-weight pediatric patients and other global markets.
- Competitive Positioning
- How Joenja's potential approval will affect Pharming's standing in the rare disease treatment space, particularly for APDS.